TP53 mutations are associated with a particular pattern of genomic imbalances in breast carcinomas

Journal of Pathology

Volumn 207, Issue 1, 2005, Pages 14-19

  Kleivi, Kristine ^a   Diep, Chieu B ^a   Pandis, Nikos ^b   Heim, Sverre ^a   Teixeira, Manuel R ^c,d   Lothe, Ragnhild A ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast cancer; Comparative genomic hybridization (CGH); Genomic complexity; Mutation analysis; TP53

Indexed keywords

GENOMIC DNA; MUTANT PROTEIN; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CHROMOSOME 16Q; CHROMOSOME 5Q; CHROMOSOME 8P; CHROMOSOME 8Q; CHROMOSOME ANALYSIS; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME LOSS; CLUSTER ANALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC DIFFERENCE; GENETIC IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UBIQUITINATION; WILD TYPE;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; CLUSTER ANALYSIS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DOWN-REGULATION; FEMALE; GENES, P53; HUMANS; MUTATION; NUCLEIC ACID HYBRIDIZATION;

EID: 23944504305     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1812     Document Type: Article

References (37)

1. Soussi T, Beroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev Cancer 2001; 1:233-240.
2. Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Res 2002;4:70-76.
3. Borresen-Dale AL. TP53 and breast cancer. Hum Mutat 2003;21:292-300.
4. Done SJ, Eskandarian S, Bull S, Redston M, Andrulis IL. p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast. J Natl Cancer Inst 2001;93:700-704.
5. Ho GH, Calvano JE, Bisogna M, Borgen PI, Rosen PP, Tan LK, et al. In microdissected ductal carcinoma in situ, HER-2 /neu amplification, but not p53 mutation, is associated with high nuclear grade and comedo histology. Cancer 2000;89:2153-2160.
6. Shackney SE, Silverman JF. Molecular evolutionary patterns in breast cancer. Adv Anat Pathol 2003;10:278-290.
7. Hislop RG, Pratt N, Stocks SC, Steel CM, Sales M, Goudie D, et al. Karyotypic aberrations of chromosomes 16 and 17 are related to survival in patients with breast cancer. Br J Surg 2002; 89:1581-1586.
8. Thompson AM, Crichton DN, Elton RA, Clay MF, Chetty U, Steel CM. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up. Br J Cancer 1998; 77:797-800.
9. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999;80:1968-1973.
10. Soong R, Iacopetta BJ, Harvey JM, Sterrett GF, Dawkins HJ, Hahnel R, et al. Detection of p53 gene mutation by rapid PCR-SSCP and its association with poor survival in breast cancer. Int J Cancer 1997;74:642-647.
11. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61:2256-2260.
12. Hoglund M, Gisselsson D, Hansen GB, Sall T, Mitelman F. Multivariate analysis of chromosomal imbalances in breast cancer delineates cytogenetic pathways and reveals complex relationships among imbalances. Cancer Res 2002;62:2675-2680.
13. Teixeira MR, Pandis N, Heim S. Cytogenetic clues to breast carcinogenesis. Genes Chromosomes Cancer 2002;33:1-16.
14. Sigurdsson S, Bodvarsdottir SK, Anamthawat-Jonsson K, Steinarsdottir M, Jonasson JG, Ogmundsdottir HM, et al. p53 abnormality and chromosomal instability in the same breast tumor cells. Cancer Genet Cytogenet 2000;121:150-155.
15. Kleivi K, Lothe RA, Heim S, Tsarouha H, Kraggerud SM, Pandis N, et al. Genome profiling of breast cancer cells selected against in vitro shows copy number changes. Genes Chromosomes Cancer 2002;33:304-309.
16. Teixeira MR, Tsarouha H, Kraggerud SM, Pandis N, Dimitriadis E, Andersen JA, et al. Evaluation of breast cancer polyclonality by combined chromosome banding and comparative genomic hybridization analysis. Neoplasia 2001;3:204-214.
17. Anonymous. WHO Classification of Tumours; Pathology & Genetics, IARC Press Lyon, 2000.
18. Yoshino K, Nishigaki K, Husimi Y. Temperature sweep gel electrophoresis: a simple method to detect point mutations. Nucleic Acids Res 1991;19:3153.
19. Lothe RA, Smith-Sorensen B, Hektoen M, Stenwig AE, Mandahl N, Saeter G, et al. Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer 2001;30:202-206.
20. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 1977; 74:5463-5467.
21. Dysvik B, Jonassen I. J-Express: exploring gene expression data using Java. Bioinformatics 2001;17:369-370.
22. IARC TP53 database. www.iarc.fr/P53/index.html [July 2004].
23. Aubele M, Werner M, Hofler H. Genetic alterations in presumptive precursor lesions of breast carcinomas. Anal Cell Pathol 2002;24:69-76.
24. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-4669.
25. de Cremoux P, Salomon AV, Liva S, Dendale R, Bouchind'homme B, Martin E, et al. p53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst 1999; 91:641-643.
26. O'Connell P. Genetic and cytogenetic analyses of breast cancer yield different perspectives of a complex disease. Breast Cancer Res Treat 2003;78:347-357.
27. Zudaire I, Odero MD, Caballero C, Valenti C, Martinez Penuela JM, Isola J, et al. Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas. Histopathology 2002;40:547-555.
28. Jong YJ, Li LH, Tsou MH, Chen YJ, Cheng SH, Wang-Wuu S, et al. Chromosomal comparative genomic hybridization abnormalities in early- and late-onset human breast cancers: correlation with disease progression and TP53 mutations. Cancer Genet Cytogenet 2004; 148:55-65.
29. Gunther K, Merkelbach-Bruse S, Amo-Takyi BK, Handt S, Schroder W, Tietze L. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-47.
30. Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Eynstein LP, Kaaresen R, et al. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci U S A 2001; 98:7952-7957.
31. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
32. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
33. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
34. Humbert S, van Vuuren H, Lutz Y, Hoeijmakers JH, Egly JM, Moncollin V. p44 and p34 subunits of the BTF2/TFIIH transcription factor have homologies with SSL1, a yeast protein involved in DNA repair. EMBO J 1994;13:2393-2398.
35. Hoege C, Pfander B, Moldovan GL, Pyrowolakis G, Jentsch S. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. Nature 2002;419:135-141.
36. Friedman E, Gejman PV, Martin GA, McCormick F. Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. Nature Genet 1993;5:242-247.
37. Yoon H, Liyanarachchi S, Wright FA, Davuluri R, Lockman JC, de la Chapelle CA, et al. Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A 2002;99:15632-15637.